Agenus 72% pathologic complete, 83% major pathologic response with neoadjuvant in dMMR colon cancer
Agenus reports 72% pathologic complete and 83% major pathologic response with neoadjuvant botensilimab plus balstilimab in dMMR colon cancer at ESMO 2026
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.